We produce medicinal cannabis for pharmaceutical companies. In 2020, we developed a cultivation technology that allows us to harvest crops every 35 days. In early 2021, the company's management made the decision to create an investment proposal based on this technology. In 2022, Cannafarm Investment LTD was established, introducing its cultivation technology and investment proposal to the general public.
Continuing to uphold a high level of raw material quality, Cannafarm has become one of the leading companies in the production of medical cannabis. Our raw materials are utilized by pharmaceutical companies specializing in manufacturing pharmaceutical products derived from hemp, such as Nabilone, Cesamet, Dronabinol-Marinol, Nabiximols, Epidiolex, and more. These medications are in high demand in the global pharmaceutical market.